NASDAQ:ANIK - Anika Therapeutics Stock Price, Price Target & More

$45.13 -0.40 (-0.88 %)

(As of 04/20/2018 04:00 PM ET)

Previous Close$45.13

Today's Range$45.03 - $46.17

52-Week Range$42.51 - $69.81

Volume88,851 shs

Average Volume88,919 shs

Market Capitalization$671.35 million

P/E Ratio23.03

Dividend YieldN/A

Beta1.73

About Anika Therapeutics (NASDAQ:ANIK)

Anika Therapeutics, Inc. is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. The Company's therapeutic offerings consist of products in the areas, including Orthobiologics, which includes viscosupplementation and regenerative orthopedic products; Dermal, which includes wound care products; Surgical, which includes products used to prevent post-surgical adhesions, and Other, which includes the Company's ophthalmic and veterinary products. The Company also offers products made from HA based on two other technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA.

Receive ANIK News and Ratings via Email

Sign-up to receive the latest news and ratings for ANIK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments

Sub-IndustryHealth Care Supplies

SectorMedical

SymbolNASDAQ:ANIK

CUSIP03525510

Webwww.anikatherapeutics.com

Phone781-457-9000

Debt

Debt-to-Equity RatioN/A

Current Ratio15.79%

Quick Ratio14.10%

Price-To-Earnings

Trailing P/E Ratio23.03

Forward P/E Ratio28.75

P/E Growth2.9

Sales & Book Value

Annual Sales$113.42 million

Price / Sales5.87

Cash Flow$2.2851 per share

Price / Cash19.75

Book Value$17.97 per share

Price / Book2.51

Profitability

EPS (Most Recent Fiscal Year)$1.96

Net Income$31.81 million

Net Margins28.05%

Return on Equity11.91%

Return on Assets11.05%

Miscellaneous

Employees123

Outstanding Shares14,740,000

How to Become a New Pot Stock Millionaire

Anika Therapeutics (NASDAQ:ANIK) Frequently Asked Questions

What is Anika Therapeutics' stock symbol?

Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."

How were Anika Therapeutics' earnings last quarter?

Anika Therapeutics Inc (NASDAQ:ANIK) issued its earnings results on Wednesday, February, 21st. The biotechnology company reported $0.38 EPS for the quarter, missing the consensus estimate of $0.41 by $0.03. The biotechnology company earned $29.39 million during the quarter, compared to analyst estimates of $29.85 million. Anika Therapeutics had a return on equity of 11.91% and a net margin of 28.05%. Anika Therapeutics's revenue was up 2.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.54 EPS. View Anika Therapeutics' Earnings History.

When is Anika Therapeutics' next earnings date?

Anika Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Anika Therapeutics.

What price target have analysts set for ANIK?

3 brokerages have issued 12-month target prices for Anika Therapeutics' stock. Their forecasts range from $57.00 to $68.00. On average, they expect Anika Therapeutics' stock price to reach $62.50 in the next twelve months. View Analyst Ratings for Anika Therapeutics.

Who are some of Anika Therapeutics' key competitors?

Some companies that are related to Anika Therapeutics include Intersect ENT (XENT), ATRION (ATRI), Orthofix (OFIX), OraSure Technologies (OSUR), Glaukos (GKOS), Luminex (LMNX), K2M Group (KTWO), MiMedx Group (MDXG), LeMaitre Vascular (LMAT), CryoLife (CRY), Cardiovascular Systems (CSII), AtriCure (ATRC), AngioDynamics (ANGO), Cerus (CERS), Tactile Systems Technology (TCMD), SurModics (SRDX), Accuray (ARAY) and Inovio Pharmaceuticals (INO).

Who are Anika Therapeutics' key executives?

Anika Therapeutics' management team includes the folowing people:

Joseph G. Darling, President, Chief Executive Officer, Director (Age 59)
Sylvia Cheung, Chief Financial Officer, Treasurer, Secretary (Age 42)
Edward Ahn Ph.D., Chief Technology and Strategy Officer (Age 45)
Richard Hague, Chief Commercial Officer (Age 57)
Joseph Lyon Bower Ph.D., Lead Independent Director (Age 79)
Raymond J. Land, Independent Director (Age 72)
Glenn R. Larsen Ph.D., Independent Director (Age 62)
Jeffrey S. Thompson, Independent Director (Age 51)
Steven E. Wheeler, Independent Director (Age 70)

Has Anika Therapeutics been receiving favorable news coverage?

Media headlines about ANIK stock have trended positive this week, according to Accern. The research group identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Anika Therapeutics earned a coverage optimism score of 0.41 on Accern's scale. They also assigned news coverage about the biotechnology company an impact score of 45.77 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are Anika Therapeutics' major shareholders?

Anika Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include SHERWOOD CHARLES H (5.15%). Company insiders that own Anika Therapeutics stock include Charles H Sherwood, Jeffery S Thompson, Joseph I Bower and Richard Hague. View Institutional Ownership Trends for Anika Therapeutics.

How do I buy shares of Anika Therapeutics?

Shares of ANIK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Anika Therapeutics' stock price today?

One share of ANIK stock can currently be purchased for approximately $45.13.

How big of a company is Anika Therapeutics?

Anika Therapeutics has a market capitalization of $671.35 million and generates $113.42 million in revenue each year. The biotechnology company earns $31.81 million in net income (profit) each year or $1.96 on an earnings per share basis. Anika Therapeutics employs 123 workers across the globe.

How can I contact Anika Therapeutics?

Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The biotechnology company can be reached via phone at 781-457-9000 or via email at [email protected]

MarketBeat Community Rating for Anika Therapeutics (ANIK)

Community Ranking:		2.9 out of 5 ( )
Outperform Votes:		130 (Vote Outperform)
Underperform Votes:		97 (Vote Underperform)
Total Votes:		227

MarketBeat's community ratings are surveys of what our community members think about Anika Therapeutics and other stocks. Vote "Outperform" if you believe ANIK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANIK will underperform the S&P 500 over the long term. You may vote once every thirty days.

Anika Therapeutics (NASDAQ:ANIK) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

3 Wall Street analysts have issued ratings and price targets for Anika Therapeutics in the last 12 months. Their average twelve-month price target is $62.50, suggesting that the stock has a possible upside of 38.49%. The high price target for ANIK is $68.00 and the low price target for ANIK is $57.00. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	N/A
Consensus Rating Score:	2.67	2.67	3.00	N/A
Ratings Breakdown:	0 Sell Rating(s) 1 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$62.50	$62.50	$57.00	N/A
Price Target Upside:	38.49% upside	8.30% upside	6.76% upside	N/A

Anika Therapeutics (NASDAQ:ANIK) Consensus Price Target History

Price Target History for Anika Therapeutics (NASDAQ:ANIK)

Anika Therapeutics (NASDAQ:ANIK) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
2/23/2018	Barrington Research	Downgrade	Outperform -> Market Perform		High
1/26/2018	Sidoti	Initiated Coverage	Buy		Low
1/24/2018	First Analysis	Upgrade	Equal Weight -> Overweight	$45.00 -> $68.00	High
4/27/2016	Northland Securities	Downgrade	Outperform -> Market Perform		N/A

(Data available from 4/21/2016 forward)

Anika Therapeutics (NASDAQ:ANIK) Earnings History and Estimates Chart

Earnings by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Anika Therapeutics (NASDAQ:ANIK) Earnings Estimates

2018 EPS Consensus Estimate: $1.57

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	2	$0.24	$0.26	$0.25
Q2 2018	2	$0.41	$0.44	$0.43
Q3 2018	2	$0.37	$0.41	$0.39
Q4 2018	2	$0.50	$0.51	$0.51

Anika Therapeutics (NASDAQ ANIK) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/2/2018		$0.32					N/A
2/21/2018	Q4 2017	$0.41	$0.38	$29.85 million	$29.39 million	View	Listen
10/25/2017	Q3 2017	$0.41	$0.46	$27.44 million	$27.18 million	View	N/A
7/26/2017	Q2 2017	$0.44	$0.7560	$27.20 million	$33.50 million	View	N/A
5/3/2017	Q1 2017	$0.3750	$0.37	$23.89 million	$23.39 million	View	Listen
2/15/2017	Q416	$0.53	$0.54	$27.84 million	$28.70 million	View	N/A
10/26/2016	Q316	$0.47	$0.59	$26.60 million	$25.79 million	View	Listen
7/27/2016	Q216	$0.44	$0.57	$24.75 million	$26.60 million	View	Listen
4/27/2016	Q116	$0.28	$0.45	$19.26 million	$22.30 million	View	Listen
2/24/2016	Q415	$0.60	$0.72	$28.19 million	$25.60 million	View	Listen
10/28/2015	Q315	$0.34	$0.55	$22.36 million	$23.70 million	View	Listen
7/29/2015	Q215	$0.34	$0.51	$21.65 million	$22.90 million	View	Listen
4/28/2015	Q115	$0.21	$0.23	$16.20 million	$15.50 million	View	Listen
2/25/2015	Q414	$0.48	$0.51	$24.60 million	$23.30 million	View	Listen
10/29/2014	Q314	$0.33	$0.40	$20.33 million	$22.10 million	View	Listen
7/30/2014	Q214	$0.57	$0.60	$28.20 million	$26.27 million	View	Listen
4/29/2014	Q114	$0.25	$0.97	$16.03 million	$34.00 million	View	N/A
2/26/2014	Q413	$0.42	$0.44	$21.91 million	$21.30 million	View	Listen
10/31/2013	Q313	$0.14	$0.33	$16.96 million	$17.80 million	View	Listen
7/31/2013	Q2 2013	$0.25	$0.40	$17.09 million	$20.80 million	View	Listen
5/1/2013	Q1 2013	$0.17	$0.21	$15.54 million	$15.25 million	View	N/A
2/27/2013	Q4 2012	$0.23	$0.42			View	N/A
10/30/2012	Q3 2012	$0.16	$0.11			View	N/A
8/1/2012	Q2 2012		$0.26			View	N/A
5/3/2012	Q1 2012		$0.14			View	N/A
2/29/2012	Q4 2011		$0.21			View	N/A
11/2/2011	Q3 2011		$0.22			View	N/A
8/4/2011	Q2 2011		$0.17			View	N/A
5/4/2011	Q1 2011		$0.02			View	N/A
3/9/2011	Q4 2010		$0.10			View	N/A
11/8/2010	Q3 2010		$0.09			View	N/A
8/9/2010	Q2 2010		$0.08			View	N/A
5/10/2010	Q1 2010		$0.05			View	N/A
3/16/2010	Q4 2009		$0.17			View	N/A
10/27/2009	Q3 2009	$0.10	$0.13			View	N/A
7/22/2009	Q2 2009	$0.08	$0.08			View	N/A
4/28/2009	Q1 2009	$0.09	$0.05			View	N/A
3/5/2009	Q4 2008	$0.13	$0.10			View	N/A
11/3/2008	Q3 2008	$0.12	$0.10			View	N/A
7/22/2008	Q2 2008	$0.05	$0.07			View	N/A
4/30/2008	Q1 2008	$0.08	$0.05			View	N/A
3/5/2008	Q4 2007	$0.13	$0.15			View	N/A

(Earnings results data provided by Zacks Investment Research)

Anika Therapeutics (NASDAQ:ANIK) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Anika Therapeutics (NASDAQ ANIK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.57%
Institutional Ownership Percentage: 84.10%

Insider Trading History for Anika Therapeutics (NASDAQ:ANIK)

Institutional Ownership by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Anika Therapeutics (NASDAQ ANIK) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/30/2017	Richard Hague	Insider	Sell	5,250	$54.48	$286,020.00
10/23/2017	Charles H Sherwood	CEO	Sell	22,228	$60.06	$1,335,013.68	158,297
10/20/2017	Charles H Sherwood	CEO	Sell	5,991	$60.04	$359,699.64	158,297
10/16/2017	Charles H Sherwood	CEO	Sell	3,293	$60.04	$197,711.72
10/13/2017	Charles H Sherwood	CEO	Sell	7,124	$60.08	$428,009.92
7/27/2017	Charles H Sherwood	CEO	Sell	63,799	$50.79	$3,240,351.21	174,705
7/5/2017	Charles H Sherwood	CEO	Sell	14,201	$50.03	$710,476.03	246,740
5/22/2017	Jeffery S Thompson	Director	Sell	10,725	$47.39	$508,257.75	15,845
11/9/2016	Joseph I Bower	Director	Sell	540	$43.39	$23,430.60	38,513
2/25/2016	Raymond J Land	Director	Sell	2,695	$43.62	$117,555.90	14,165
2/27/2015	Raymond J Land	Director	Sell	4,621	$39.49	$182,483.29
5/1/2014	Charles H Sherwood	CEO	Sell	83,780	$44.32	$3,713,129.60
2/28/2014	Charles H Sherwood	CEO	Sell	200,000	$41.70	$8,340,000.00
8/22/2013	John C Moran	Director	Sell	5,000	$24.35	$121,750.00
8/8/2013	Steve E Wheeler	Director	Sell	26,984	$23.61	$637,092.24
8/7/2013	Steve E Wheeler	Director	Sell	11,016	$27.01	$297,542.16
8/6/2013	Farmaceutici S.P.A. Fidia	Major Shareholder	Sell	1,270,000	$24.52	$31,140,400.00
7/15/2013	Charles H Sherwood	CEO	Sell	75,000	$20.11	$1,508,250.00
7/9/2013	Charles H Sherwood	CEO	Sell	49,185	$18.06	$888,281.10
7/5/2013	Charles H Sherwood	CEO	Sell	34,662	$18.01	$624,262.62
6/19/2013	Charles H Sherwood	CEO	Sell	1,847	$18.00	$33,246.00

(Data available from 1/1/2013 forward)

Anika Therapeutics (NASDAQ ANIK) News Headlines

Source:

Date	Headline
	Anika Therapeutics (ANIK) Downgraded to Sell at BidaskClub www.americanbankingnews.com - April 20 at 11:54 AM
	Anika to Issue First-Quarter 2018 Financial Results and Business Highlights on Wednesday, May 2 finance.yahoo.com - April 18 at 5:32 PM
	Anika Therapeutics Inc (ANIK) Given Consensus Rating of "Hold" by Analysts www.americanbankingnews.com - April 12 at 11:20 PM
	Anika Therapeutics (ANIK) Downgraded by ValuEngine www.americanbankingnews.com - April 12 at 10:19 PM
	Anika Therapeutics (ANIK) Stock Rating Upgraded by BidaskClub www.americanbankingnews.com - April 12 at 7:25 PM
	Anika Announces Plans to Showcase HYALOFAST Hyaluronic Acid-Based Scaffold at the 2018 World Congress of the International Cartilage Repair Society finance.yahoo.com - April 6 at 8:46 AM
	Brokerages Anticipate Anika Therapeutics Inc (ANIK) to Post $0.25 Earnings Per Share www.americanbankingnews.com - March 30 at 3:24 AM
	With A -2.25% Earnings Drop, Is Anika Therapeutics Inc’s (FRA:AKP) A Concern? finance.yahoo.com - March 29 at 8:44 AM
	Anika Therapeutics Inc (ANIK) Receives Average Recommendation of "Buy" from Brokerages www.americanbankingnews.com - March 26 at 1:32 AM
	Edited Transcript of ANIK earnings conference call or presentation 22-Feb-18 2:00pm GMT finance.yahoo.com - March 22 at 5:24 PM
	Brokerages Set $68.00 Target Price for Anika Therapeutics Inc (ANIK) www.americanbankingnews.com - March 20 at 1:18 AM
	Director's Letter Micro Cap Summary - March 2018 seekingalpha.com - March 15 at 5:53 PM
	Anika to Showcase Commercial and Pipeline Portfolio at 2018 AAOS Annual Meeting finance.yahoo.com - March 14 at 8:58 AM
	Critical Review: Anika Therapeutics (ANIK) and Onconova Therapeutics (ONTX) www.americanbankingnews.com - March 10 at 12:17 PM
	Joseph Darling Named CEO and Director of Anika Therapeutics - GlobeNewswire (press release) globenewswire.com - March 6 at 8:32 AM
	Anika to Showcase Commercial and Pipeline Portfolio at 2018 AAOS Annual Meeting - GlobeNewswire (press release) globenewswire.com - March 6 at 8:32 AM
	Analysts Set $68.00 Price Target for Anika Therapeutics Inc (ANIK) www.americanbankingnews.com - March 5 at 5:14 AM
	Anika Therapeutics Inc (ANIK) Holdings Lifted by Bbva Compass Bancshares Inc. www.americanbankingnews.com - March 1 at 4:56 AM
	First Analysis Comments on Anika Therapeutics Inc's FY2019 Earnings (ANIK) www.americanbankingnews.com - February 28 at 3:18 PM
	First Analysis Brokers Decrease Earnings Estimates for Anika Therapeutics Inc (ANIK) www.americanbankingnews.com - February 27 at 8:38 AM
	New Strong Sell Stocks for February 27th finance.yahoo.com - February 27 at 8:37 AM
	Anika Therapeutics Inc (ANIK) Files 10-K for the Fiscal Year Ended on December 31, 2017 finance.yahoo.com - February 27 at 8:37 AM
	Anika Therapeutics (ANIK) Downgraded by Zacks Investment Research to "Sell" www.americanbankingnews.com - February 26 at 5:24 PM
	Equities Analysts Issue Forecasts for Anika Therapeutics Inc's Q1 2018 Earnings (ANIK) www.americanbankingnews.com - February 26 at 3:18 AM
	Anika Therapeutics (ANIK) Lowered to Hold at BidaskClub www.americanbankingnews.com - February 24 at 3:52 PM
	Anika Therapeutics' (ANIK) CEO Charles Sherwood on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha seekingalpha.com - February 24 at 8:30 AM
	Anika Therapeutics (NASDAQ:ANIK) Shares Stunted By Increased ... - Benzinga www.benzinga.com - February 24 at 8:30 AM
	Kamada (KMDA) and Anika Therapeutics (ANIK) Critical Survey www.americanbankingnews.com - February 24 at 1:06 AM
	Anika Therapeutics Shares Stunted By Increased Investment, Barrington Says In Downgrade finance.yahoo.com - February 23 at 5:42 PM
	Anika Therapeutics (ANIK) Rating Lowered to Market Perform at Barrington Research www.americanbankingnews.com - February 23 at 4:28 PM
	Anika Therapeutics Inc. 2017 Q4 - Results - Earnings Call Slides seekingalpha.com - February 22 at 5:27 PM
	Anika Therapeutics (ANIK) Releases Earnings Results, Misses Expectations By $0.03 EPS www.americanbankingnews.com - February 22 at 3:26 PM
	Anika Reports Fourth Quarter and Full Year 2017 Financial Results finance.yahoo.com - February 21 at 5:17 PM
	When Should You Buy Anika Therapeutics Inc (NASDAQ:ANIK)? finance.yahoo.com - February 21 at 5:17 PM
	Zacks: Anika Therapeutics Inc (ANIK) Receives Average Recommendation of "Strong Buy" from Brokerages www.americanbankingnews.com - February 18 at 3:14 AM
	Anika Therapeutics (ANIK) Set to Announce Earnings on Wednesday www.americanbankingnews.com - February 14 at 4:32 AM
	Anika to Issue Fourth-Quarter 2017 Financial Results and Business Highlights on Wednesday, February 21 finance.yahoo.com - February 8 at 8:21 AM
	Anika Therapeutics (ANIK) to Release Earnings on Tuesday www.americanbankingnews.com - February 6 at 3:12 AM
	Analysts Set $62.50 Target Price for Anika Therapeutics Inc (ANIK) www.americanbankingnews.com - February 3 at 3:26 AM
	Anika Therapeutics Announces Strategic Collaboration with the Institute of Integrative Biology at the University of Liverpool to Develop an Innovative Therapy for Osteoarthritis finance.yahoo.com - February 2 at 9:46 AM
	First Analysis Upgrades Anika Therapeutics (ANIK) to "Overweight" www.americanbankingnews.com - January 28 at 6:36 PM
	Anika Therapeutics (ANIK) Lifted to Buy at BidaskClub www.americanbankingnews.com - January 27 at 10:16 AM
	Sidoti Initiates Coverage on Anika Therapeutics (ANIK) www.americanbankingnews.com - January 26 at 4:54 PM
	First Analysis Weighs in on Anika Therapeutics Inc's Q4 2017 Earnings (ANIK) www.americanbankingnews.com - January 26 at 6:46 AM
	Anika Therapeutics Expands Strategic Collaboration with the Institute for Applied Life Sciences (IALS) at the University of Massachusetts Amherst to Develop Innovative Therapy for Rheumatoid Arthritis finance.yahoo.com - January 25 at 9:46 AM
	First Analysis Weighs in on Anika Therapeutics Inc's FY2017 Earnings (ANIK) www.americanbankingnews.com - January 25 at 7:58 AM
	Recent Analysis Shows Darling Ingredients, Principal Financial Group, UGI, Cass Information, WD-40, and Anika Therapeutics Market Influences — Renewed Outlook, Key Drivers of Growth finance.yahoo.com - January 22 at 9:22 AM
	Analysts Set $57.00 Price Target for Anika Therapeutics Inc. (ANIK) www.americanbankingnews.com - January 19 at 3:58 AM
	Anika Therapeutics (ANIK) and 3SBio (SSRX) Head to Head Analysis www.americanbankingnews.com - January 6 at 1:36 PM
	Anika Therapeutics Inc. (ANIK) Given Consensus Recommendation of "Strong Buy" by Brokerages www.americanbankingnews.com - January 4 at 2:00 AM

Anika Therapeutics (NASDAQ:ANIK) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Anika Therapeutics (NASDAQ:ANIK) Income Statement, Balance Sheet and Cash Flow Statement

Anika Therapeutics (NASDAQ ANIK) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff